TABLE 1.

Review of Studies Evaluating Treatment Response to PRRT Monotherapy in mMCC (n = 10)

Study	Age (y)	Sex	Primary location	Other sites of involvement	Type of radiotracer, cumulative dose, and no. of cycles	Treatments before PRRT					Survival from start of PRRT (mo)	Response to PRRT
Study	Age (y)	Sex	Primary location	Other sites of involvement	Type of radiotracer, cumulative dose, and no. of cycles	Surgery	EBRT	Chemo.	SSA	ICI	Survival from start of PRRT (mo)	Response to PRRT
Meier (7)	83	F	Facial (left cheek) (3 cm)	Cervical LNs	⁹⁰Y-DOTATOC, 15.72 GBq, 4 cycles	Yes	Yes	Yes	No	No	27	CR
Bodei (8)	78^*	F^*	Leg (left)^*	Pelvic LNs^*	⁹⁰Y-DOTATOC, 9.6 GBq, 3 cycles^*	Yes^*	Yes^*	No^*	No^*	No^*	7^*	PD^*
Maecke (9)	43	F	Head	NA	⁹⁰Y-DOTATOC, 5.4 GBq/m², 4 cycles	NA	NA	NA	NA	NA	>19^*	CR
Imhof (10)	70^*	M^*	NA^*	NA^*	⁹⁰Y-DOTATOC, 8.14 GBq, 1 cycle^*	Yes^*	No^*	Yes^*	No^*	No^*	6.1^*	PD^*
	77^*	M^*	NA^*	Liver, bone^*	⁹⁰Y-DOTATOC, 6.66 GBq, 1 cycle^*	Yes^*	Yes^*	No^*	No^*	No^*	1^*	PD^*
	69^*	F^*	NA^*	NA^*	⁹⁰Y-DOTATOC, 5.37 GBq, 1 cycle^*	No^*	Yes^*	Yes^*	No^*	No^*	1.2^*	PD^*
	55^*	M^*	NA^*	Liver^*	⁹⁰Y-DOTATOC, 8.14 GBq, 1 cycle^*	Yes^*	No^*	Yes^*	No^*	No^*	1.7^*	PD^*
	54^*	F^*	NA^*	NA^*	⁹⁰Y-DOTATOC, 12.96 GBq, 2 cycles^*	Yes^*	No^*	No^*	No^*	No^*	13.9^*	PR^*
	66^*	M^*	NA^*	Liver^*	⁹⁰Y-DOTATOC, 14.06 GBq, 2 cycles^*	Yes^*	Yes^*	Yes^*	No^*	No^*	4.5^*	SD^*
	83^*	F^*	NA^*	NA^*	⁹⁰Y-DOTATOC, 15.73 GBq, 4 cycles^*	Yes^*	Yes^*	No^*	No^*	No^*	9.1^*	SD^*
	69^*	F^*	NA^*	Liver^*	⁹⁰Y-DOTATOC, 11.1 GBq, 2 cycles^*	Yes^*	No^*	No^*	No^*	No^*	9.7^*	PR^*
Villard (11)	76^*	F^*	NA^*	NA^*	¹⁷⁷Lu-DOTATOC, 12.95 GBq, 2 cycles; ⁹⁰Y-DOTATOC, 13.88 GBq, 2 cycles^*	Yes^*	No^*	No^*	No^*	No^*	15.1^*	SD^*
	73^*	F^*	NA^*	NA^*	¹⁷⁷Lu-DOTATOC, 14.43 GBq, 2 cycles; ⁹⁰Y-DOTATOC, 14.43 GBq, 2 cycles^*	Yes^*	Yes^*	Yes^*	No^*	No^*	9.8^*	SD^*
Romer (12)	76^*	F^*	NA^*	Bone^*	¹⁷⁷Lu-DOTATOC, 7.4 GBq, 1 cycle^*	No^*	Yes^*	Yes^*	No^*	No^*	0.7^*	PD^*
	53^*	M^*	NA^*	NA^*	¹⁷⁷Lu-DOTATOC, 7.4 GBq, 1 cycle^*	No^*	No^*	Yes^*	No^*	No^*	1.3^*	PD^*
Basu (2)	54	M	Facial (right malar)	Cervical LNs, liver	¹⁷⁷Lu-DOTATATE, 13.14 GBq, 2 cycles	Yes	No	Yes	Yes	Yes^*	>3	PR
Nilica (13)	65^*	M^*	Arm (right forearm)^*	Widespread (LNs, liver, bone, peritoneum, heart)^*	¹⁷⁷Lu-DOTATATE, 14.2 GBq, 2 cycles; ⁹⁰Y-DOTATOC, 2.4 GBq, 1 cycle^*	Yes^*	Yes^*	Yes^*^†	No^*	No^*	5^*	PD^*
Noorelahi (14)	59	M	Axilla (right) (9 cm)	Subpectoral and axillary LNs	¹⁷⁷Lu-DOTATOC, 10.62 GBq, 2 cycles	Yes	Yes	Yes	NA	NA	NA	PD
Moghadam (3)	77	M	Facial (right malar)	Extensive LNs (cervical, supraclavicular, mediastinal, axillary, abdominal)	¹⁷⁷Lu-DOTATATE, 5.5 GBq, 1 cycle	Yes	Yes	Yes	Yes	No	2^*^‡	PR

↵* Data were obtained after personal communication with corresponding authors of that article/unpublished data.
↵† Intracardiac instillation of chemotherapeutic drugs due to cardiac involvement.
↵‡ Death due to other cause (acute respiratory distress syndrome).
EBRT = external-beam radiation therapy; chemo. = chemotherapy; SSA = somatostatin analogue; ICI = immune checkpoint inhibitor; LN = lymph node; CR = complete response; PD = progressive disease; NA = not available; PR = partial response; SD = stable disease.